Brief: Innate Pharma Q1 Revenue Down At Eur 2.6 Mln

Innate Pharma SA

10/05/2022 06:06

May 10 (Reuters) - Innate Pharma SA  IPH.PA :
    * CASH POSITION TO EUR 131.7 MILLION AS OF MARCH 31, 2022
    * REVENUES FOR FIRST THREE MONTHS OF 2022 AMOUNTED TO EUR
2.6
MILLION (EUR 4.5 MILLION FOR SAME PERIOD IN 2021)
    * ASTRAZENECA-SPONSORED PHASE 3 INTERLINK-1 TRIAL OF
MONALIZUMAB
PLUS CETUXIMAB IN IMMUNO-ONCOLOGY-PRETREATED HEAD AND NECK
CANCER IS ONGOING WITH FINAL DATA EXPECTED IN 2024
    * DATA FOR THE PHASE 1 TRIAL IN SOLID TUMORS WITH IPH5201
ALONE OR
IN COMBINATION WITH DURVALUMAB (PD-L1) ARE EXPECTED TO BE
PRESENTED IN 2023

Source text for Eikon:  ID:nBwxjSpca 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))